We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
-5.01%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$380M
AUM Growth
-$34.7M
Cap. Flow
+$1.1M
Cap. Flow %
0.29%
Top 10 Hldgs %
55.07%
Holding
91
New
23
Increased
22
Reduced
16
Closed
28

Top Buys

Rank Stock Value
1
OFIX icon
Orthofix Medical
OFIX
+$13.4M
2
BMY icon
Bristol-Myers Squibb
BMY
+$13.1M
3
CNC icon
Centene
CNC
+$12.1M
4
MCK icon
McKesson
MCK
+$7.93M
5
AVTR icon
Avantor
AVTR
+$6.38M

Top Sells

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$21.3M
2
COR icon
Cencora
COR
+$15.3M
3
XRAY icon
Dentsply Sirona
XRAY
+$9.62M
4
BDX icon
Becton Dickinson
BDX
+$8.66M
5
SIBN icon
SI-BONE Inc
SIBN
+$7.34M

Sector Composition

Rank Sector Weight
1 Healthcare 70.45%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
26
Insmed
INSM
$28.7B
$3.88M 1.02%
165,280
+76,069
+85% +$1.77M
ALBO
27
DELISTED
Albireo Pharma Inc
ALBO
$3.6M 0.95%
120,834
+55,196
+84% +$1.62M
LKFT
28
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.71B
$3.25M 0.86%
+52,400
New +$3.21M
IDXX icon
29
Idexx Laboratories
IDXX
$46.5B
$3.13M 0.83%
+5,729
New +$3.01M
QGEN icon
30
Qiagen
QGEN
$8.61B
$2.73M 0.72%
+52,487
New +$2.71M
PINC
31
DELISTED
Premier
PINC
$2.69M 0.71%
+75,632
New +$2.82M
STRO icon
32
Sutro Biopharma
STRO
$400M
$2.44M 0.64%
29,651
+18,471
+165% +$1.76M
MTD icon
33
Mettler-Toledo International
MTD
$28.5B
$2.42M 0.64%
+1,765
New +$2.55M
FATE icon
34
Fate Therapeutics
FATE
$290M
$2.32M 0.61%
59,732
+22,407
+60% +$868K
TNDM icon
35
Tandem Diabetes Care
TNDM
$1.29B
$2.12M 0.56%
+18,236
New +$2.13M
KRTX
36
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$1.95M 0.51%
+15,342
New +$1.73M
TXG icon
37
10x Genomics
TXG
$5.79B
$1.9M 0.5%
+24,923
New +$2.18M
BHVN
38
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$1.83M 0.48%
15,400
+9,331
+154% +$1.16M
VRTX icon
39
Vertex Pharmaceuticals
VRTX
$123B
$1.82M 0.48%
+6,982
New +$1.66M
ALNY icon
40
Alnylam Pharmaceuticals
ALNY
$28.9B
$1.7M 0.45%
+10,379
New +$1.58M
AFMD
41
DELISTED
Affimed
AFMD
$1.55M 0.41%
+35,449
New +$1.54M
VRDN icon
42
Viridian Therapeutics
VRDN
$2.49B
$1.54M 0.41%
83,217
+15,767
+23% +$303K
GBT
43
DELISTED
Global Blood Therapeutics, Inc.
GBT
$1.5M 0.39%
43,250
+453
+1% +$13.5K
IMUX icon
44
Immunic
IMUX
$198M
$1.48M 0.39%
13,057
-5,397
-29% -$625K
ARGX icon
45
argenx
ARGX
$54.8B
$1.41M 0.37%
+4,480
New +$1.3M
ICUI icon
46
ICU Medical
ICUI
$4.16B
$1.36M 0.36%
6,093
-1,673
-22% -$375K
RCUS icon
47
Arcus Biosciences
RCUS
$3.56B
$1.22M 0.32%
+38,650
New +$1.3M
RYTM icon
48
Rhythm Pharmaceuticals
RYTM
$7.72B
$1.22M 0.32%
105,792
-91,670
-46% -$805K
XBI icon
49
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$1.13M 0.3%
126,000
+11,700
+10% +$1.08M
DVA icon
50
PUT
DaVita
DVA
$11.5B
$1.13M 0.3%
+10,000
New +$1.12M
1
2
3 4

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, Endurant Capital Management held 91 positions worth $380M, down 8.4% from $414M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Endurant Capital Management's Q1 2022 filing shows 23 new, 22 increased, 16 reduced and 28 closed positions. Its largest new stake was Bristol-Myers Squibb: 194,684 shares worth $14.2M. The largest sale was Sanofi, an estimated $21.3M.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, down from 72% a quarter earlier, followed by Industrials.

  • Endurant Capital Management's largest Q1 2022 buy was Bristol-Myers Squibb: 194,684 shares worth $14.2M.
  • Endurant Capital Management added most to Orthofix Medical in Q1 2022, an estimated $13.4M increase.
  • Endurant Capital Management's biggest Q1 2022 reduction was SI-BONE Inc, cutting an estimated $7.34M.
  • Endurant Capital Management fully exited Sanofi in Q1 2022, selling an estimated $21.3M.
  • Endurant Capital Management's ten largest holdings make up 55% of its $380M portfolio in Q1 2022.
  • Endurant Capital Management opened 23 new positions and closed 28 in Q1 2022.
  • Endurant Capital Management's portfolio value fell 8.4% quarter-over-quarter to $380M.

Based on Endurant Capital Management's 13F filing for Q1 2022, filed 16 May 2022.